Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

Phase 1

Completed

Conditions: B-cell Non-Hodgkin Lymphoma

Interventions: Drug: Mosunetuzumab
Drug: Cyclophosphamide
Drug: Polatuzumab Vedotin
Drug: Rituxumab
Drug: Doxorubicin
Drug: Prednisone
Drug: Vincristine
Drug: Tocilizumab

First Posted Date: 2018-09-19

Last Posted Date: 2024-12-18

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 117

Registration Number: NCT03677141

Locations: 🇺🇸
University of Alabama Birmingham, Birmingham, Alabama, United States
🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
University of California; Moores Cancer Center, La Jolla, California, United States

and more 38 locations

Immunosuppressant Regimens for Living Fetuses Study

Not Applicable

Conditions: Undifferentiated Connective Tissue Disease
Recurrent Pregnancy Loss

Interventions: Drug: Prednisone
Drug: Hydroxychloroquine
Drug: Aspirin
Drug: low molecular weight heparin

First Posted Date: 2018-09-14

Last Posted Date: 2019-08-12

Lead Sponsor: RenJi Hospital

Target Recruit Count: 420

Registration Number: NCT03671174

Locations: 🇨🇳
Renji Hospital, Shanghai, Shanghai, China

Effect of Short Course of Glucocorticoid in Patients With Diabetes Mellitus(DM) Type 2

Early Phase 1

Completed

Conditions: Diabetes
Hyperglycemia Steroid-induced

Interventions: Drug: Prednisone

First Posted Date: 2018-09-07

Last Posted Date: 2023-09-26

Lead Sponsor: Cook County Health

Target Recruit Count: 10

Registration Number: NCT03661684

Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer

Phase 2

Terminated

Conditions: Stage IV Prostate Cancer AJCC v8
Metastatic Malignant Neoplasm in the Bone
Metastatic Prostate Carcinoma
Prostate Adenocarcinoma
Prostate Small Cell Neuroendocrine Carcinoma
Stage IVA Prostate Cancer AJCC v8
Stage IVB Prostate Cancer AJCC v8
Castration-Sensitive Prostate Carcinoma

Interventions: Drug: Antiandrogen Therapy
Drug: Abiraterone Acetate
Drug: Prednisone
Radiation: Radiation Therapy

First Posted Date: 2018-08-28

Last Posted Date: 2023-10-26

Lead Sponsor: University of Washington

Target Recruit Count: 10

Registration Number: NCT03649841

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Characterization of the Molecular Mechanisms Involved in Delayed-Type Hypersensitivity Reactions to House Dust Mite, Diphencyprone, Nickel, and Tuberculin Purified Protein Derivative in Healthy Volunteers

Not Applicable

Completed

Conditions: Delayed Type Hypersensitivity

Interventions: Drug: Placebo
Drug: Prednisone

First Posted Date: 2018-08-10

Last Posted Date: 2020-07-17

Lead Sponsor: Innovaderm Research Inc.

Target Recruit Count: 54

Registration Number: NCT03625219

Locations: 🇨🇦
Innovaderm Research Inc., Montreal, Quebec, Canada

Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients

Phase 2

Conditions: Experimental Tumor

Interventions: Drug: Chidamide
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Etoposide
Drug: Prednisone

First Posted Date: 2018-08-06

Last Posted Date: 2018-09-04

Lead Sponsor: Peking University

Target Recruit Count: 114

Registration Number: NCT03617432

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, China

Ruxolitinib Plus LVP in Patients With R/R ETP-ALL

Phase 1

Conditions: Acute T Cell Leukemia

Interventions: Drug: Ruxolitinib
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2018-08-03

Last Posted Date: 2018-08-03

Lead Sponsor: Sichuan University

Target Recruit Count: 12

Registration Number: NCT03613428

Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA

Phase 3

Terminated

Conditions: Giant Cell Arteritis

Interventions: Drug: Sarilumab matching placebo
Drug: Sarilumab SAR153191
Drug: Prednisone
Drug: Prednisone matching placebo

First Posted Date: 2018-07-26

Last Posted Date: 2022-03-28

Lead Sponsor: Sanofi

Target Recruit Count: 83

Registration Number: NCT03600805

Locations: 🇵🇹
Investigational Site Number 6200001, Almada, Portugal
🇩🇰
Investigational Site Number 2080002, Aarhus C, Denmark
🇫🇷
Investigational Site Number 2500006, Pessac, France

and more 58 locations

Low-dose ITI Strategy for Children in Hemophilia A With High-titer Inhibitor and Poor ITI Risk in China

Phase 4

Conditions: Hemophilia A With Inhibitor

Interventions: Drug: Coagulation Factor VIII
Drug: Prednisone
Drug: Rituximab

First Posted Date: 2018-07-26

Last Posted Date: 2018-07-26

Lead Sponsor: Beijing Children's Hospital

Target Recruit Count: 55

Registration Number: NCT03598725

Locations: 🇨🇳
Beijing Children's Hospital, Beijing, Beijing, China

Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica

Phase 3

Terminated

Conditions: Polymyalgia Rheumatica

Interventions: Drug: Sarilumab SAR153191 (REGN88)
Drug: Sarilumab-matching placebo
Drug: Prednisone
Drug: Prednisone-matching placebo

First Posted Date: 2018-07-26

Last Posted Date: 2022-06-10

Lead Sponsor: Sanofi

Target Recruit Count: 118

Registration Number: NCT03600818

Locations: 🇺🇸
Investigational Site Number 8400009, Stamford, Connecticut, United States
🇦🇷
Investigational Site Number 0320001, Buenos Aires, Argentina
🇷🇺
Investigational Site Number 6430001, Moscow, Russian Federation

and more 81 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy